menu
    • menu

    Company profile for Mesoblast

    NEW Drugs in Dev: 11
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Mesoblast is a world leader in developing innovative cellular medicines.The Company has established what it believes is the industry’s most clinically advanced and diverse portfolio of cell-based product candidates with three programs in Phase 3 clinical studies. Consistent and durable clinical outcomes have been demonstrated across multiple difficult-to-treat diseases.The Company has leveraged its proprietary technology pla...
    Mesoblast is a world leader in developing innovative cellular medicines.The Company has established what it believes is the industry’s most clinically advanced and diverse portfolio of cell-based product candidates with three programs in Phase 3 clinical studies. Consistent and durable clinical outcomes have been demonstrated across multiple difficult-to-treat diseases.The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    MesoblastAustralia Flag
    Country
    Country
    Australia
    Address
    Address
    55 Collins Street Level 38 Melbourne 3000
    Telephone
    Telephone
    +61 3 9639 6036
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.mesoblast.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/mesoblast
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    PBP World Meeting

    Not Confirmed

    envelop Contact Supplier

    PBP World Meeting

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Mesoblast To Host R&D Day On April 8, 2026
    Mesoblast To Host R&D Day On April 8, 2026

    17 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/17/3257833/0/en/Mesoblast-to-Host-R-D-Day-on-April-8-2026.html

    GLOBENEWSWIRE
    17 Mar 2026
    Share Share
    Mesoblast Names Dr. Montagut as Head of Clinical, Medical Affairs
    Mesoblast Names Dr. Montagut as Head of Clinical, Medical Affairs

    11 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/11/3254223/0/en/Dr-Teresa-Montagut-Appointed-as-Clinical-Development-and-Medical-Affairs-Head-at-Mesoblast.html

    GLOBENEWSWIRE
    11 Mar 2026
    Share Share
    Ryoncil Profits Underpinning Substantial Growth Pipeline
    Ryoncil Profits Underpinning Substantial Growth Pipeline

    26 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/27/3246245/0/en/Ryoncil-Profits-Underpinning-Substantial-Growth-Pipeline.html

    GLOBENEWSWIRE
    26 Feb 2026
    Share Share
    Ryoncil Shows High Survival in EIND for SR-aGVHD
    Ryoncil Shows High Survival in EIND for SR-aGVHD

    11 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/11/3236794/0/en/High-Survival-Rates-With-Ryoncil-in-EIND-Program-Emphasize-Importance-of-Earlier-Use-in-Both-Children-and-Adults-With-SR-aGvHD.html

    GLOBENEWSWIRE
    11 Feb 2026
    Share Share
    Ryoncil Net Revenues Hit $30M in Quarter
    Ryoncil Net Revenues Hit $30M in Quarter

    28 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/28/3228137/0/en/Ryoncil-Net-Revenues-Increase-for-the-Quarter-to-US-30M.html

    GLOBENEWSWIRE
    28 Jan 2026
    Share Share
    Ryoncil Demonstrates 84% Survival Rate In Children With SR-aGvHD
    Ryoncil Demonstrates 84% Survival Rate In Children With SR-aGvHD

    26 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/26/3226046/0/en/Real-World-Commercial-Experience-with-Ryoncil-Shows-84-Survival-of-Children-with-SR-aGvHD-After-Completing-28-Days-of-Treatment.html

    GLOBENEWSWIRE
    26 Jan 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search